

# Fanni Rencz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2238568/publications.pdf>

Version: 2024-02-01

96  
papers

1,829  
citations

304743

22  
h-index

345221

36  
g-index

101  
all docs

101  
docs citations

101  
times ranked

2047  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis. <i>European Journal of Health Economics</i> , 2023, 24, 139-152.	2.8	6
2	Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 399-408.	1.4	13
3	Measurement properties of the ICECAP-A capability well-being instrument among dermatological patients. <i>Quality of Life Research</i> , 2022, 31, 903-915.	3.1	4
4	A comparative study on the measurement properties of Dermatology Life Quality Index (DLQI), DLQI- $\leq 16$ and Skindex-16*. <i>British Journal of Dermatology</i> , 2022, 186, 485-495.	1.5	16
5	POSB379 Measurement Properties of DLQI, DLQI-R and Skindex-16: A Comparative Study. <i>Value in Health</i> , 2022, 25, S235.	0.3	0
6	A qualitative investigation of the relevance of skin irritation and self-confidence bolt-ons and their conceptual overlap with the EQ-5D in patients with psoriasis. <i>Quality of Life Research</i> , 2022, 31, 3049-3060.	3.1	7
7	Assessment of health state utilities in dermatology: an experimental time trade-off value set for the dermatology life quality index. <i>Health and Quality of Life Outcomes</i> , 2022, 20, .	2.4	1
8	General and Skin-Specific Health-Related Quality of Life in Patients With Atopic Dermatitis Before and During the COVID-19 Pandemic. <i>Dermatitis</i> , 2022, 33, S92-S103.	1.6	5
9	Disease burden of patients with pemphigus from a societal perspective. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 77-86.	1.4	9
10	Validation of the Hungarian version of the CarerQol instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary. <i>Quality of Life Research</i> , 2021, 30, 629-641.	3.1	6
11	Subjective expectations regarding longevity and future health: a cross-sectional survey among patients with Crohn's disease. <i>Colorectal Disease</i> , 2021, 23, 105-113.	1.4	2
12	The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa. <i>Quality of Life Research</i> , 2021, 30, 1477-1490.	3.1	12
13	A Rasch model analysis of two interpretations of "not relevant" responses on the Dermatology Life Quality Index (DLQI). <i>Quality of Life Research</i> , 2021, 30, 2375-2386.	3.1	10
14	Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters' Levels, but Has No Effect on Body Composition Parameters. <i>Life</i> , 2021, 11, 535.	2.4	6
15	Questionnaire Modifications and Alternative Scoring Methods of the Dermatology Life Quality Index: A Systematic Review. <i>Value in Health</i> , 2021, 24, 1158-1171.	0.3	12
16	Impact of Interleukin-17 Inhibitor Therapy on Arterial Intima-media Thickness among Severe Psoriatic Patients. <i>Life</i> , 2021, 11, 919.	2.4	9
17	Musculoskeletal health and capability wellbeing: Associations between the HAQ-DI, ICECAP-A and ICECAP-O measures in a population survey. <i>Musculoskeletal Science and Practice</i> , 2021, 55, 102420.	1.3	1
18	047 Interleukin-17 inhibitor therapy reduces arterial intima-media thickness in severe psoriasis. <i>Journal of Investigative Dermatology</i> , 2021, 141, S156.	0.7	0

#	ARTICLE	IF	CITATIONS
19	DLQI scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea. <i>British Journal of Dermatology</i> , 2020, 182, 1167-1175.	1.5	25
20	Cross-country generalizability of quality of life scores in atopic dermatitis. <i>British Journal of Dermatology</i> , 2020, 182, 1083-1083.	1.5	2
21	Acceptable health and ageing: results of a cross-sectional study from Hungary. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 346.	2.4	3
22	Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. <i>Value in Health</i> , 2020, 23, 1235-1245.	0.3	58
23	Capability of well-being: validation of the Hungarian version of the ICECAP-A and ICECAP-O questionnaires and population normative data. <i>Quality of Life Research</i> , 2020, 29, 2863-2874.	3.1	13
24	Validity of EQ-5D-5L, Skindex-16, DLQI and DLQI-R in patients with hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2584-2592.	2.4	25
25	A new self-reported measure of disease severity of scalp hair loss in alopecia areata. <i>British Journal of Dermatology</i> , 2020, 183, 986-987.	1.5	0
26	Dermatology Life Quality Index (DLQI) score bands are applicable to DLQI-Relevant (DLQI-R) scoring. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e484-e486.	2.4	7
27	Did You Get What You Wanted? Patient Satisfaction and Congruence Between Preferred and Perceived Roles in Medical Decision Making in a Hungarian National Survey. <i>Value in Health Regional Issues</i> , 2020, 22, 61-67.	1.2	8
28	Exploring eHealth Literacy and Patient-Reported Experiences With Outpatient Care in the Hungarian General Adult Population: Cross-Sectional Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e19013.	4.3	17
29	PSY32 Health Utility Assessment By Composite Time Trade-Off in Patients with Hidradenitis Suppurativa. <i>Value in Health</i> , 2020, 23, S748.	0.3	0
30	Validity of the EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus. <i>British Journal of Dermatology</i> , 2019, 180, 802-809.	1.5	27
31	Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 537-549.	1.4	19
32	Patient-assigned health utility values for controlled and uncontrolled pemphigus vulgaris and foliaceus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2106-2113.	2.4	7
33	EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus. <i>British Journal of Dermatology</i> , 2019, 180, e126.	1.5	0
34	Validity of the EQ-5D in pemphigus. <i>British Journal of Dermatology</i> , 2019, 180, e110.	1.5	0
35	Determinants of the acceptability of health problems in different ages: exploring a new application of the EQ VAS. <i>European Journal of Health Economics</i> , 2019, 20, 31-41.	2.8	6
36	Psychometric properties of the Hungarian version of the eHealth Literacy Scale. <i>European Journal of Health Economics</i> , 2019, 20, 57-69.	2.8	49

#	ARTICLE	IF	CITATIONS
37	Is the trend of increasing use of patient-reported outcome measures in medical device studies the sign of shift towards value-based purchasing in Europe?. <i>European Journal of Health Economics</i> , 2019, 20, 133-140.	2.8	18
38	Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies. <i>European Journal of Health Economics</i> , 2019, 20, 141-154.	2.8	12
39	Validity and reliability of the 9-item Shared Decision Making Questionnaire (SDM-Q-9) in a national survey in Hungary. <i>European Journal of Health Economics</i> , 2019, 20, 43-55.	2.8	25
40	A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases. <i>European Journal of Health Economics</i> , 2019, 20, 119-132.	2.8	17
41	Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary. <i>European Journal of Health Economics</i> , 2019, 20, 17-30.	2.8	11
42	Patient and general population values for luminal and perianal fistulising Crohn's disease health states. <i>European Journal of Health Economics</i> , 2019, 20, 91-100.	2.8	5
43	Cost-of-illness studies in nine Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2019, 20, 155-172.	2.8	23
44	Subjective well-being in patients with pemphigus: a path analysis. <i>European Journal of Health Economics</i> , 2019, 20, 101-107.	2.8	7
45	EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review. <i>European Journal of Health Economics</i> , 2019, 20, 109-117.	2.8	8
46	Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e267-e269.	2.4	19
47	Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease. <i>Quality of Life Research</i> , 2019, 28, 141-152.	3.1	41
48	Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. <i>Advances in Therapy</i> , 2019, 36, 721-745.	2.9	7
49	Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. <i>Current Medicinal Chemistry</i> , 2019, 26, 259-269.	2.4	34
50	Impact of dupilumab on health-related quality of life in patients with atopic dermatitis. <i>British Journal of Dermatology</i> , 2018, 178, 319-320.	1.5	0
51	Patients with psoriasis on a new trajectory: long-term improvement in quality of life with biologics. <i>British Journal of Dermatology</i> , 2018, 178, 29-30.	1.5	1
52	Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. <i>United European Gastroenterology Journal</i> , 2018, 6, 310-321.	3.8	20
53	A detailed analysis of 'not relevant' responses on the <sc>DLQI</sc> in psoriasis: potential biases in treatment decisions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 783-790.	2.4	40
54	Is the DLQI appropriate for medical decision-making in psoriasis patients?. <i>Archives of Dermatological Research</i> , 2018, 310, 47-55.	1.9	24

#	ARTICLE	IF	CITATIONS
55	PRM185 - COMPARISON OF THE MEASUREMENT PROPERTIES OF THE EQ-5D-5L AND EQ-5D-3L IN PATIENTS WITH CROHN'S DISEASE. <i>Value in Health</i> , 2018, 21, S388.	0.3	0
56	PMU90 - HEALTH PROBLEMS IN HUNGARIAN ELDERLY OUTPATIENTS MEASURED BY THE EQ-5D-3L: COMPARISON WITH A POPULATION NORM FOR CENTRAL EASTERN EUROPE. <i>Value in Health</i> , 2018, 21, S323.	0.3	1
57	Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis. <i>British Journal of Dermatology</i> , 2018, 179, 1102-1108.	1.5	42
58	Association between quality of life and clinical characteristics in patients with morphea. <i>Quality of Life Research</i> , 2018, 27, 2525-2532.	3.1	21
59	EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature. <i>Kardiologia Polska</i> , 2018, 76, 860-870.	0.6	19
60	Exploring the Relationship between Quality of Life (EQ-5D) and Clinical Measures in Adult Attention Deficit Hyperactivity Disorder (ADHD). <i>Applied Research in Quality of Life</i> , 2017, 12, 409-424.	2.4	4
61	Comparing self-perceived and estimated fracture risk by FRAX® of women with osteoporosis. <i>Archives of Osteoporosis</i> , 2017, 12, 4.	2.4	3
62	The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. <i>Advances in Therapy</i> , 2017, 34, 1128-1144.	2.9	64
63	Expression of G protein-coupled oestrogen receptor in melanoma and in pregnancy-associated melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1453-1461.	2.4	16
64	Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 597-606.	1.4	22
65	EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis. <i>Rheumatology International</i> , 2017, 37, 1957-1977.	3.0	9
66	Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. <i>Quality of Life Research</i> , 2017, 26, 3409-3419.	3.1	51
67	Long-term costs and survival of prostate cancer: a population-based study. <i>International Urology and Nephrology</i> , 2017, 49, 1707-1714.	1.4	5
68	Bleeding out the quality-adjusted life years: evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods. <i>Pain</i> , 2017, 158, 2259-2267.	4.2	30
69	Access to biologicals in Crohn's disease in ten European countries. <i>World Journal of Gastroenterology</i> , 2017, 23, 6294.	3.3	35
70	Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 139-147.	1.9	15
71	Subjective health expectations of patients with age-related macular degeneration treated with antiVEGF drugs. <i>BMC Geriatrics</i> , 2017, 17, 233.	2.7	17
72	A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 1-7.	1.4	44

#	ARTICLE	IF	CITATIONS
73	Alopecia areata and health-related quality of life: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2016, 175, 561-571.	1.5	144
74	Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment. <i>British Journal of Dermatology</i> , 2016, 175, 593-599.	1.5	15
75	A Cost-Effectiveness Analysis of Biosimilar Infliximab (Inflixtra®) For The Treatment of Psoriatic Arthritis In Nine European Countries. <i>Value in Health</i> , 2016, 19, A540-A541.	0.3	1
76	EQ-5D Studies in Diseases of The Circulatory System in Eight Central and Eastern European Countries. <i>Value in Health</i> , 2016, 19, A657-A658.	0.3	0
77	Epidemiology and Survival in Prostate Cancer; A Population Based Study Analysing The Hungarian National Health Insurance Found Database. <i>Value in Health</i> , 2016, 19, A716.	0.3	0
78	Willingness To Pay For Primary Dysmenorrhea Health States. <i>Value in Health</i> , 2016, 19, A404-A405.	0.3	0
79	Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists. <i>Value in Health Regional Issues</i> , 2016, 10, 85-90.	1.2	11
80	EQ-5D in Central and Eastern Europe: 2000-2015. <i>Quality of Life Research</i> , 2016, 25, 2693-2710.	3.1	103
81	Measurement Properties of The EQ-5D-5L Compared To The EQ-5D-3L In Psoriasis Patients. <i>Value in Health</i> , 2016, 19, A572-A573.	0.3	0
82	Patients' access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 942-943.	0.9	21
83	Discrepancies between the Dermatology Life Quality Index and utility scores. <i>Quality of Life Research</i> , 2016, 25, 1687-1696.	3.1	16
84	Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 22-27.	1.5	30
85	Social Utility Values for Pemphigus Vulgaris and Foliaceus: A Composite Time Trade-Off Study. <i>Value in Health</i> , 2015, 18, A673.	0.3	1
86	Use of biologics for psoriasis in Central and Eastern European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2222-2230.	2.4	41
87	Health state utilities for migraine based on attack frequency: a time trade-off study. <i>Neurological Sciences</i> , 2015, 36, 197-202.	1.9	12
88	Retrospective Analysis of Clinicopathological Characteristics of Pregnancy Associated Melanoma. <i>Pathology and Oncology Research</i> , 2015, 21, 1265-1271.	1.9	13
89	Cost of illness of medically treated benign prostatic hyperplasia in Hungary. <i>International Urology and Nephrology</i> , 2015, 47, 1241-1249.	1.4	11
90	Health-related quality of life and its determinants in pemphigus: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2015, 173, 1076-1080.	1.5	24

#	ARTICLE	IF	CITATIONS
91	Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1398-1405.	2.4	21
92	Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe. <i>World Journal of Gastroenterology</i> , 2015, 21, 1728.	3.3	64
93	Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey. <i>Archives of Iranian Medicine</i> , 2015, 18, 153-9.	0.6	19
94	Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. <i>European Journal of Health Economics</i> , 2014, 15, 13-25.	2.8	70
95	Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2014, 15, 27-34.	2.8	14
96	Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. <i>European Journal of Health Economics</i> , 2014, 15, 111-119.	2.8	60